Frequently used treatment options in patients with inhibitors include high-intensity factor concentrate regimens and require a major commitment of time and resources from patients and their families. These regimens include: 1) ITI therapy to eradicate recently developed inhibitors,2) administration of higher doses of factor VIII (>50 IU/kg) to control bleeding for patients with low-titer inhibitors (5 BU) These therapeutic strategies pose significant challenges to patients and their families due to cost, time commitments, and the need to maintain rigorous adherence to the protocols being used.